MannKind
Logotype for MannKind Corporation

MannKind (MNKD) investor relations material

MannKind Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for MannKind Corporation
Jefferies Global Healthcare Conference summary18 Nov, 2026

Growth outlook and commercial performance

  • Three growth engines for 2027: FUROSCIX ReadyFlow, Afrezza, and expanded United Therapeutics programs; nintedanib DPI represents a longer-term IPF opportunity.

  • Revenue CAGR was 42% over the past five years, driven by royalties, commercial collaboration revenue, FUROSCIX, and Afrezza; Q4 profitability and record revenue were expected.

  • Q4 revenue was forecast at ~$38 million, subject to quarter-end demand trends.

FUROSCIX ReadyFlow

  • ReadyFlow received approval in Q3; ~75% of FUROSCIX shipments had converted, while 90% of community demand prescriptions were for ReadyFlow.

  • Four target settings span worsening at home, emergency departments, inpatient IV diuretics, and post-discharge readmission; each represents nearly 1 million patients annually.

  • Hospital adoption had slowed, with expansion planned; inpatient discharge and readmission prevention were identified as major growth opportunities.

Afrezza and pediatric initiatives

  • Pediatric Afrezza adoption was strong: new-to-brand prescriptions rose 80%, about one in four patients at quarter-end were pediatric, and pediatric market share was 2x adult share in the first 90 days.

  • In 2027, plans include refocusing sales efforts on adults, expanding cardiovascular reach, and continuing pediatric support; a two-unit cartridge is also planned.

  • INHALE-1ST had ~35 participants; the goal is 100 by mid-2027 and a data readout, testing inhaled insulin in newly diagnosed children.

  • Inhale IQ, an inhaler adapter integrating dose tracking with CGM data, was being submitted to the FDA, with a launch targeted for 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next MannKind earnings date

Logotype for MannKind Corporation
Q4 202626 Feb, 2027
MannKind
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next MannKind earnings date

Logotype for MannKind Corporation
Q4 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for patients with diabetes and pulmonary diseases. The company’s flagship product is an inhalable insulin used to manage blood sugar levels in adults with diabetes. MannKind is also exploring its proprietary Technosphere platform for the delivery of other therapeutic agents via inhalation, aiming to improve treatment options for various chronic conditions. The company is headquartered in Danbury, Connecticut, and its shares are listed on the NASDAQ.